ArticleCancer cell2016
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 130 citations in OpenAlex.
- Icaritin Sensitizes Hepatocellular Carcinoma to PD-L1 Therapy by NQO1-Dependent Ferroptosis Induction.Phytotherapy research : PTR · 2026Article
- β-Lapachone-Induced Oxidative Stress Causes PARP-Dependent NADNeurochemical research · 2026Article
- Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Low-dose X-ray-activated radiodynamic therapy via a lutetium-coordinated nanoplatform synergizing PARP inhibition and ferroptosis.Journal of nanobiotechnology · 2026Article
- Open-Sourced In Silico Drug Screening.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Novel Cyano-Artemisinin Dimer ZQJ29 Targets PARP1 to Induce Ferroptosis in Pancreatic Cancer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Chlorogenic Acid Enhances Beta-Lapachone-Induced Cell Death by Suppressing Autophagy in NQO1-Positive Cancer Cells.Cell biology international · 2025Article
- Unraveling systemic responses to NQO1-activated IB-DNQ and Rucaparib single and dual agent therapy in triple-negative breast cancers.bioRxiv : the preprint server for biology · 2025Article
- A small molecule cryptotanshinone induces non-enzymatic NQO1-dependent necrosis in cancer cells through the JNK1/2/Iron/PARP/calcium pathway.Acta pharmaceutica Sinica. B · 2025Article
- β-lapachone suppresses carcinogenesis of cervical cancer via interaction with AKT1.Frontiers in pharmacology · 2025Article
- Simultaneous Targeting of NQO1 and SOD1 Eradicates Breast Cancer Stem Cells via Mitochondrial Futile Redox Cycling.Cancer research · 2024Article
- Review
- Isopentyl-Deoxynboquinone Induces Mitochondrial Dysfunction and G2/M Phase Cell Cycle Arrest to Selectively KillAntioxidants & redox signaling · 2024Article
- β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers.Oncoimmunology · 2024Article
- Article
- The Application of Biomedicine in Chemodynamic Therapy: From Material Design to Improved Strategies.Bioengineering (Basel, Switzerland) · 2023Review
- A sense-antisense RNA interaction promotes breast cancer metastasis via regulation of NQO1 expression.Nature cancer · 2023Article
- Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.Antioxidants (Basel, Switzerland) · 2023Article
- Theranostics for Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 1 country.
Xiumei HuangDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Edward A MoteaDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Zachary R MooreDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Jun YaoDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Ying DongDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Gaurab ChakrabartiDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Jessica A KilgoreDepartment of Biochemistry, SCCC, UTSW, Dallas, TX 75390, USA.
Molly A SilversDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Praveen L PatidarDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Agnieszka CholkaDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Farjana FattahDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA.
Yoonjeong ChaImmuneering Corporation, One Broadway 14th Floor, Cambridge, MA 02142, USA.
Glenda G Anderson5Degrees Bio., Inc., 111 North Market Street #300, San Jose, CA 95113, USA.
Rebecca KuskoImmuneering Corporation, One Broadway 14th Floor, Cambridge, MA 02142, USA.
Michael PeytonDepartment of Internal Medicine, Division of Hematology-Oncology, UTSW, Dallas, TX 75390, USA.
Jingsheng YanDepartment of Biostatistics, UTSW, Dallas, TX 75390, USA.
Xian-Jin XieDepartment of Biostatistics, UTSW, Dallas, TX 75390, USA.
Venetia SarodeDepartment of Pathology, UTSW, Dallas, TX 75390, USA.
Noelle S WilliamsDepartment of Biochemistry, SCCC, UTSW, Dallas, TX 75390, USA.
John D MinnaDepartment of Internal Medicine, Division of Hematology-Oncology, UTSW, Dallas, TX 75390, USA.
Muhammad BegDepartment of Internal Medicine, Division of Hematology-Oncology, UTSW, Dallas, TX 75390, USA.
David E GerberDepartment of Internal Medicine, Division of Hematology-Oncology, UTSW, Dallas, TX 75390, USA.
Erik A BeyDepartment of Pharmaceutical Sciences, West Virginia University Cancer Institute, Morgantown, WV 26506, USA. Electronic address: erik.bey@hsc.wvu.edu.
David A BoothmanDepartments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center (SCCC), UT Southwestern Medical Center (UTSW), Dallas, TX 75390, USA. Electronic address: david.boothman@utsouthwestern.edu.
Southwestern Medical Center · USTexas Oncology · USImmuneering (United States)The University of Texas at Dallas · USWest Virginia University · US
Funding
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4MUT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MUse of Beta-Lapachone for Lung Cancer ChemotherapyR01CA102792 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BOOTHMAN, DAVID A · 2003 to 2017
$5.3MWest Virginia Flow Cytometry Core FacilityP30GM103488 · NIGMS · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2012 to 2016
$4.8MCOBRE FOR SIGNAL TRANSDUCTION AND CANCER PHASE IIIP30RR032138 · NCRR · WEST VIRGINIA UNIVERSITY · PI GIBSON, LAURA F. · 2011 to 2011
$1.1MNCI NIH HHS P30 CA142543NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA102792NCRR NIH HHS P30 RR032138NIGMS NIH HHS P30 GM103488NIGMS NIH HHS U54 GM104942
Abstract
Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are combined, synergistic antitumor activity results from sustained NAD(P)H levels that refuel NQO1-dependent futile redox drug recycling. Significant oxygen-consumption-rate/reactive oxygen species cause dramatic DNA lesion increases that are not repaired due to PARP inhibition. In NQO1
Indexed as
AnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationCell SurvivalDNA DamageDrug SynergismGene Expression Regulation, NeoplasticHumansLung NeoplasmsMiceNAD(P)H Dehydrogenase (Quinone)NaphthoquinonesPancreatic NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsReactive Oxygen Speciesbeta-lapachoneNAD(P)H Dehydrogenase (Quinone)NaphthoquinonesNQO1 protein, humanPoly(ADP-ribose) Polymerase InhibitorsReactive Oxygen SpeciesARQ761combination chemotherapyNQO1NQO1 bioctivatable drugsNSCLCOlaparibPARP1PDAROSRucaparibsynthetic lethalityβ-lapachone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.